| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| Other Sizes |
| Targets |
Mps1-IN-1 dihydrochloride targets monopolar spindle 1 (Mps1) kinase, also known as TTK protein kinase. Mps1 is a key regulator of the spindle assembly checkpoint (SAC), which ensures proper chromosome segregation during mitosis. Mps1-IN-1 is an ATP-competitive inhibitor with an IC50 of 367 nM and a Kd of 27 nM. It exhibits >1000-fold selectivity against a panel of 352 kinases, with the exceptions of ALK and Ltk.
|
|---|---|
| ln Vitro |
HCT116 cell growth is inhibited by Mps1-IN-1 diHClide (2–10 μM; 96 hours) to 33% of DMSO control [1]. In a dose-dependent manner, Mps1-IN-1 dihydrochloride (0.3-10 μM; 4 h) causes bypass of checkpoint-mediated mitotic arrest. Dose-dependent reduction in mitotic duration is observed upon administration of Mps1-IN-1 dihydrochloride (10 µM), with nearly all U2OS cells entering anaphase in less than 20 minutes [1]. Reduced phosphorylation-induced mobility alterations in UTRM10 LAP-Mps1 WT cells indicate a dose-dependent decrease of hyperphosphorylated Mps1 caused by Mps1-IN-1 diHClide (0.5, 2, 10 μM). When nocodazole was used to inhibit Mps1-IN-1 (5, 10 μM) mitosis, 4c pHistone H3-negative cells accumulated in U2OS cells in a dose-dependent manner [1]. Chromosome misalignment and missegregation are prominent symptoms of accelerated mitotic kinetics in Mps1-IN-1-treated cells, which directly affects genome stability [1]. With the exception of Alk and Ltk, Mps1-IN-1 dihydrochloride is more than 1000 times selective against the 352-member kinase group [1].
In vitro, Mps1-IN-1 dihydrochloride inhibits Mps1 kinase activity with an IC50 of 367 nM. In a dose-dependent manner, Mps1-IN-1 dihydrochloride (0.3-10 µM; 4 h) causes bypass of checkpoint-mediated mitotic arrest. A dose-dependent reduction in mitotic duration is observed upon administration of Mps1-IN-1 dihydrochloride (10 µM). The compound (0.5, 2, 10 µM) causes a dose-dependent reduction in hyper-phosphorylated Mps1 as demonstrated by a decrease in phosphorylation-induced mobility shift in UTRM10 LAP-Mps1 WT cells. |
| ln Vivo |
In vivo activity data for Mps1-IN-1 dihydrochloride are not extensively detailed in the available sources. As a research compound, it is used to study the role of Mps1 in mitosis and the spindle assembly checkpoint. The compound may be used in cancer research to investigate the effects of SAC inhibition on tumor cell proliferation and chromosome instability.
|
| Enzyme Assay |
The in vitro enzyme assay for Mps1-IN-1 dihydrochloride involves measuring the inhibition of Mps1 kinase activity. Recombinant Mps1 is incubated with a substrate peptide and ATP in the presence of varying compound concentrations. The IC50 value (367 nM) is determined by quantifying the reduction in substrate phosphorylation using radioactive or fluorescence-based assays.
|
| Cell Assay |
Cell proliferation experiment [1]
Cell Types: HCT116 Cell Tested Concentrations: 2, 5, 10 μM Incubation Duration: 96 hrs (hours) Experimental Results: The proliferation ability of HCT116 cells was diminished to 33% of the DMSO control. Cell cycle analysis[1] Cell Types: U2OS Cell Tested Concentrations: 0.3, 0.5, 1, 2, 5, 10 μM Incubation Duration: 4 hrs (hours) Experimental Results: diminished levels of cyclin B protein, which accumulates in G2 phase and is present in the spindle Checkpoints persist during activation. Western Blot Analysis [1] Cell Types: HeLa and U2OS cells Tested Concentrations: 10 μM Incubation Duration: 1 hour pretreatment before paclitaxel and MG132 Experimental Results: Caused a dose-dependent decrease in the phosphorylation status of Aurora B threonine 232 (Thr232). Cellular assays are performed using UTRM10 LAP-Mps1 WT cells. Cells are treated with Mps1-IN-1 dihydrochloride at concentrations of 0.5, 2, and 10 µM. Mps1 phosphorylation is assessed by Western blotting, and a dose-dependent reduction in hyper-phosphorylated Mps1 is observed. Mitotic duration and checkpoint bypass are assessed by time-lapse microscopy. |
| Animal Protocol |
In vivo animal studies for Mps1-IN-1 dihydrochloride are not detailed in the available sources. The compound is a research tool for studying Mps1 function in mitosis. Specific animal models, dosing regimens, and efficacy data have not been reported in the supplier documentation.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for Mps1-IN-1 dihydrochloride are not available in the provided sources. The compound has a molecular weight of 608.58 g/mol and a molecular formula of C28H35Cl2N5O4S. It should be stored desiccated at room temperature. The compound is soluble in DMSO.
|
| Toxicity/Toxicokinetics |
Toxicity data for Mps1-IN-1 dihydrochloride are not reported in the available sources. As a research compound, it is not intended for therapeutic use. The compound has been evaluated in cell-based assays at concentrations up to 10 µM. Specific toxicological profiles have not been characterized.
|
| References | |
| Additional Infomation |
Mps1-IN-1 dihydrochloride is a research compound for studying Mps1 kinase function in mitosis and the spindle assembly checkpoint. It is a potent and selective ATP-competitive inhibitor with an IC50 of 367 nM and a Kd of 27 nM. The compound exhibits >1000-fold selectivity against a panel of 352 kinases. It is available from commercial suppliers for research use only.
|
| Molecular Formula |
C28H35CL2N5O4S
|
|---|---|
| Molecular Weight |
608.579603433609
|
| Exact Mass |
607.178
|
| CAS # |
1883548-93-3
|
| PubChem CID |
91691119
|
| Appearance |
Typically exists as solid at room temperature
|
| Hydrogen Bond Donor Count |
6
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
8
|
| Heavy Atom Count |
40
|
| Complexity |
862
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CC(C)S(=O)(=O)C1=CC=CC=C1NC2=CC(=NC3=C2C=CN3)NC4=C(C=C(C=C4)N5CCC(CC5)O)OC.Cl.Cl
|
| InChi Key |
HFJLUXGXTPNYTQ-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C28H33N5O4S.2ClH/c1-18(2)38(35,36)26-7-5-4-6-23(26)30-24-17-27(32-28-21(24)10-13-29-28)31-22-9-8-19(16-25(22)37-3)33-14-11-20(34)12-15-33;;/h4-10,13,16-18,20,34H,11-12,14-15H2,1-3H3,(H3,29,30,31,32);2*1H
|
| Chemical Name |
1-[3-methoxy-4-[[4-(2-propan-2-ylsulfonylanilino)-1H-pyrrolo[2,3-b]pyridin-6-yl]amino]phenyl]piperidin-4-ol;dihydrochloride
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.6432 mL | 8.2158 mL | 16.4317 mL | |
| 5 mM | 0.3286 mL | 1.6432 mL | 3.2863 mL | |
| 10 mM | 0.1643 mL | 0.8216 mL | 1.6432 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
